Latest Breaking News On - Neutrophil extracellular traps - Page 1 : comparemela.com

Aethlon Inks Materials Transfer Deal For Santersus NucleoCapture And HemoNucleoCapture Devices

(RTTNews) - Medical therapeutic company Aethlon Medical, Inc. (AEMD) announced Wednesday that it entered into a Materials Transfer Agreement (MTA).

City ofUnited kingdomSantersu nucleocaptureAethlon hemopurifierAethlon medical incAethlon medicalMaterials transfer agreementNeutrophil extracellular traps

Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG s NucleoCapture and HemoNucleoCapture Devices

/PRNewswire/ Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening.

City ofUnited kingdomJames frakesSusan noonanSantersu nucleocaptureAethlon hemopurifierScott maguireJim frakesSecurities exchangeExchange commissionCompany contactAethlon medical incSa noonan communicationsDrug administrationPrnewswire aethlon medical incCompany annual report on form

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Enters Into Materials Transfer Agreement for Santersus AG s NucleoCapture and HemoNucleoCapture Devices

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Enters Into Materials Transfer Agreement for Santersus AG s NucleoCapture and HemoNucleoCapture Devices

City ofUnited kingdomJames frakesSantersu nucleocaptureScott maguireJim frakesAethlon hemopurifierSusan noonanUs food drug administrationCompany annual report on formAethlon medical incAthelon medical incDrug administrationCompany contactExchange commissionSa noonan communications

Purple Biotech Reports Third Quarter 2023 Financial Results

Purple Biotech Reports Third Quarter 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBristol myers squibbGil efronDrug administrationExchange commissionAmerican association for cancer researchPancreatic cancer program advancesOwners of the companyDevelopment expensesPurple biotech ltdCompany contactInternational financial reporting standardsInitial activityNeck cancer demonstratedEscalation studypatients enrollmentCancertrial ahead

Purple Biotech Reports Third Quarter 2023 Financial

Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24.

United statesGil efronBristol myers squibbLior fhimaOwners of the companyAmerican association for cancer researchPurple biotech ltdPancreatic cancer program advancesDrug administrationExchange commissionDevelopment expensesCompany contactInternational financial reporting standardsInitial activityNeck cancer demonstratedCancertrial ahead